The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).
 
Dirk Schadendorf
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Research Funding - MSD
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
 
Reinhard Dummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche Pharma AG
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MELA Sciences (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); OncoSec (Inst); Roche Pharma AG (Inst)
 
Caroline Robert
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
 
Omid Hamid
Consulting or Advisory Role - Merck
Research Funding - Merck (Inst)
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
 
Alfons JM van den Eertwegh
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; MSD; Novartis; Roche Pharma AG
Travel, Accommodations, Expenses - Astellas Pharma; MSD; Pfizer; Roche Pharma AG
 
Lee D. Cranmer
Honoraria - Bristol-Myers Squibb; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Amgen; Bristol-Myers Squibb; Caris MPI; Castle Biosciences; Genentech/Roche; GlaxoSmithKline; Merck
 
Steven O'Day
Honoraria - Merck
Consulting or Advisory Role - Merck
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Igor Puzanov
No Relationships to Disclose
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - MSD
 
Christian U. Blank
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Roche Pharma AG (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - MSD; Roche Pharma AG
 
April K. Salama
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst)
 
Carmen Loquai
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Roche Pharma AG
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche Pharma AG
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche Pharma AG
 
Janice M. Mehnert
Consulting or Advisory Role - Amgen/Dompé (Inst)
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Other Relationship - Amgen
 
Yang Wang
Employment - Merck
 
Scot Ebbinghaus
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Soonmo Peter Kang
Employment - Merck
Stock and Other Ownership Interests - Agenus; Celgene; Celldex; Endocyte; Macrogenics; Merck; Pharmacyclics
 
Wei Zhou
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Antoni Ribas
Stock and Other Ownership Interests - Compugen; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Merck Sharp & Dohme (Inst)